Skip to content

To evaluate the Safety and efficacy of Unani formulations Qurs Asfar for symptomatic relief in Shara Muzmin (Chronic Urticaria)

Clinical Validation of Unani Pharmacopoeial Formulationâ?? Qurs Asfar for symptomatic relief in Shara Muzmin (Chronic Urticaria)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/10/006295
Enrollment
540
Registered
2015-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Shara Muzmin (Chronic Urticaria) Health Condition 2: L509- Urticaria, unspecified

Interventions

Intervention1: Qurs Asfar : Qurs Asfar 775 mg Orally Twice a day with water for 14 days Control Intervention1: nil: nil

Sponsors

Central Council for Research in Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients of either sex with age 18-55 years • Clinically diagnosed case of chronic urticaria (urticaria more than six weeks) presenting with any one of the following signs and symptoms. ï?? H/o recurrent evanescent skin eruptions ï?? Feeling of heat and pricking sensation just before the appearance of lesions1,2,3. ï?? Edematous wheals surrounded by a red flare1,2,3,4,5,6,7. ï?? Intense itching which is usually very intense with burning sensation and increase in the evening time1,2,3,4,7. ï?? Mild to severe pruritus ï?? Physical urticaria (cold, heat, sun exposure, vibration, pressure, sweating and exercise) ï?? Dermatographism

Exclusion criteria

Exclusion criteria: 1. Patients with difficulty in breathing in acute urticaria. 2. Urticaria due to worm infestation 3. Anaphylactic shock 4. Known cases of Thyroid disease/ Lupus/Rheumatoid arthritis 5. Known cases of severe Renal/ Hepatic/ Cardiac ailments 6. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptoms of Shara Muzmin (Chronic Urticaria)Timepoint: 14 days

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: 14 days

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026